Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2014-05-29

FDA Approved: AZILECT — Supplemental Application (Teva Neuroscience, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for AZILECT (rasagiline mesylate) from Teva Neuroscience, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Azilect (rasagiline)

Snippet

SUPPL AP for AZILECT (RASAGILINE MESYLATE)